Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women
Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the acceptability of randomization to contraceptive
options and estimate the effect of progestin contraception on HIV genital shedding and
inflammatory/immune perturbations in women who may or may not be on antiretroviral therapy,
as well as in HIV-uninfected women controls. It is hypothesized that progestin-containing
contraception will lead to inflammatory changes that may affect the local immune activity,
influencing HIV acquisition or transmissibility risk.
Phase:
Phase 4
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
Bill and Melinda Gates Foundation Fogarty International Center of the National Institute of Health John E. Fogarty International Center (FIC) National Institutes of Health (NIH) United States Agency for International Development (USAID)